Telomeres and telomerase

Telomeres and telomerase are, respectively, the repetitive nucleotide sequences and associated proteins that cap the ends of linear chromosomes, and the reverse transcriptase that extends them. Telomeres shorten each time a somatic cell divides; when they become critically short the cell triggers a DNA damage response and enters senescence or apoptosis. Telomere attrition is one of the Hallmarks of aging, but its causal weight in normal human aging is smaller and more disputed than popular accounts suggest.

§Structure and function

Human telomeres consist of thousands of tandem TTAGGG repeats ending in a single-stranded 3′ overhang that folds back to form a lasso-like t-loop. Six proteins — TRF1, TRF2, POT1, TIN2, TPP1 and RAP1, collectively the shelterin complex — bind the repeats and hide the chromosome end from the repair machinery. Without shelterin, the cell reads a natural chromosome terminus as a double-strand break and attempts to fuse it to another chromosome, producing the end-to-end fusions and breakage cycles that characterize genomic crisis.

The capping function, not the length as such, is what matters. A telomere can be long and dysfunctional if shelterin is disrupted, and short telomeres in a cell with intact capping may not signal damage until a threshold is crossed. The relationship between average telomere length and cellular behaviour is therefore indirect: it is the shortest telomere in a cell, not the mean, that determines when arrest occurs.

§The end-replication problem and the Hayflick limit

DNA polymerase cannot replicate the extreme 5′ end of a lagging strand, so each round of replication removes a small stretch of terminal sequence. James Watson described the geometry of this in 1972, and Alexey Olovnikov independently proposed that it would impose a division counter on somatic cells and explain the replicative limit Leonard Hayflick had observed in cultured human fibroblasts.¹ Human somatic cells in culture typically manage a few dozen population doublings before arresting.

Introducing the catalytic subunit of telomerase into normal human cells prevents that arrest and allows indefinite proliferation, which confirmed the causal link between telomere maintenance and the replicative limit.² This is the basis of most immortalized cell lines used in research, and telomerase reactivation is part of what makes induced pluripotent stem cells proliferate without limit.

§Telomerase

1. 1978
   Telomere sequence determined
   Elizabeth Blackburn and Joseph Gall identify the repeated sequence at the chromosome ends of the ciliate Tetrahymena.
2. 1985
   Telomerase identified
   Carol Greider and Blackburn detect an enzyme activity in Tetrahymena extracts that adds telomeric repeats to chromosome ends.
3. 1998
   Human cells immortalized
   Bodnar and colleagues show that expressing hTERT in normal human cells extends their replicative lifespan indefinitely.
4. 2009
   Nobel Prize
   Blackburn, Greider and Jack Szostak share the prize in Physiology or Medicine for the discovery of telomeres and telomerase.
5. 2024
   Telomerase inhibitor approved
   Imetelstat, which targets the telomerase RNA template, is approved in the United States for anaemia in lower-risk myelodysplastic syndromes.

Telomerase is a ribonucleoprotein: the protein subunit TERT copies a template carried within the RNA subunit TERC. It is active in germ cells, embryonic stem cells, and — at lower levels — in adult stem and progenitor compartments and activated lymphocytes. Most differentiated human somatic cells express little or none, which is why they age replicatively.

Loss-of-function mutations in telomerase components and in shelterin cause the short telomere syndromes, a spectrum that includes dyskeratosis congenita, aplastic anaemia, and a substantial fraction of familial idiopathic pulmonary fibrosis.³ These disorders provide the cleanest human evidence that telomere maintenance matters: patients show premature failure of exactly the high-turnover tissues that depend on it, connecting the mechanism directly to stem cell exhaustion. They do not show that ordinary aging is telomere-driven, since the affected tissues are a subset and the phenotype is not general.

§A weak biomarker

Average leukocyte telomere length is easy to sell as a measure of Biological age and difficult to defend as one. Inter-individual variation at any given chronological age is large relative to the average annual rate of loss, so a single measurement carries little information about an individual. Measurement methods disagree: quantitative PCR, the cheapest approach and the one behind most consumer tests, has poor within-sample reproducibility compared with terminal restriction fragment analysis or flow-FISH, and results are not comparable across laboratories. Longitudinal studies sometimes report telomere lengthening in individuals over follow-up intervals, which is a strong sign of measurement noise.

Contested

Consumer telomere tests, sold through the same direct-to-consumer testing channels as broad blood panels, report a length and an implied "cellular age". No professional body endorses telomere length as a clinical measure of aging outside the diagnosis of telomere biology disorders, and methylation-based clocks outperform it as mortality predictors in most head-to-head comparisons.

Associations between telomere length and lifestyle factors such as physical activity or stress have been widely reported and are generally small, inconsistently replicated, and vulnerable to confounding. The field's own retrospective assessment is that early effect sizes were inflated by small samples and selective reporting, a pattern common across candidate aging biomarkers.

§The cancer tradeoff

The large majority of human cancers reactivate telomerase, most often through mutations in the TERT promoter that create new transcription factor binding sites; the remainder maintain telomeres through a recombination-based mechanism called alternative lengthening of telomeres. Unlimited division requires solving the end-replication problem, and telomere attrition is therefore a genuine tumour-suppressive barrier in long-lived, large-bodied species.

This makes telomerase therapy for aging structurally awkward. Mendelian randomization studies using genetic variants that raise telomere length find increased risk of several cancers, notably glioma and melanoma, alongside modestly reduced risk of some non-neoplastic conditions.⁴ Germline POT1 mutations that lengthen telomeres cause familial cancer predisposition syndromes. Any intervention that adds telomere reserve across the body would be pushing on a trait for which natural selection appears to have found a compromise.

§Therapeutic attempts

Work in mice has been more encouraging than the cancer argument would suggest, with the caveat that laboratory mice have very long telomeres and constitutive telomerase in many tissues, making them a poor model for the human situation. Systemic delivery of a Tert transgene using an adeno-associated viral vector to adult mice extended median lifespan and improved several health measures without an observed increase in cancer incidence.⁵ Similar work in cancer-resistant mouse backgrounds also extended lifespan.

In humans the record is thinner and less reputable. Supplements marketed as telomerase activators, principally cycloastragenol derivatives, rest on small studies with weak endpoints and are sold under the rules that govern supplements rather than as drugs. Self-experimental telomerase gene therapy outside clinical trials has been publicized by at least one biotechnology executive, with self-reported telomere measurements as the only outcome and no independent verification. Meanwhile the pharmaceutical use of telomere biology has gone the opposite direction: the first approved drug in the area inhibits telomerase to treat a haematological malignancy.

§Open problems

The comparative biology does not fit a simple story. Mice have far longer telomeres than humans and live roughly two years. Some negligibly senescent species maintain telomerase in somatic tissue and control cancer by other means. Whether telomere attrition contributes materially to the trajectory of a normally aging human, as opposed to setting a limit in specific high-turnover compartments, is not resolved, and the question bears directly on how much of the damage-repair agenda and the geroscience programme should be allocated to it. The one point of agreement is that raising telomerase everywhere is not a plausible route to extended maximum lifespan without a solution to the cancer problem, and no such solution exists.

§See also

• Cellular senescence
• Hallmarks of aging
• Epigenetic clocks
• Aging biomarkers
• Gene therapy for aging
• Negligible senescence

§References